A Phase 2 Study of Allogeneic Mesenchymal Stromal Cells for Luminal Crohn's Disease Refractory to Biologic Therapy
Clinical Gastroenterology and Hepatology2013Vol. 12(1), pp. 64–71
Citations Over TimeTop 1% of 2013 papers
Geoffrey M Forbes, Marian Sturm, Rupert W. Leong, Miles Sparrow, Dev Segarajasingam, Adrian G. Cummins, Michael Phillips, Richard Herrmann
Related Papers
- → Loss of Response and Requirement of Infliximab Dose Intensification in Crohn's Disease: A Review(2009)661 cited
- → Trough Levels and Antibodies to Infliximab May Not Predict Response to Intensification of Infliximab Therapy in Patients With Inflammatory Bowel Disease(2011)111 cited
- Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response.(2006)
- → Anti-infliximab antibodies are already detectable in most patients with rheumatoid arthritis halfway through an infusioncycle: an open-label pharmacokinetic cohort study(2011)41 cited
- [Management of failure of infliximab in inflammatory bowel disease].(2011)